Sign in to view content

Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2022

Related

Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021
96-Week Visual and Expanded Anatomical Outcomes of Brolucizumab Versus Aflibercept in Patients With nAMD: Results From HAWK and HARRIER
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2019
Episode 4: 3-year Results of the TREX-AMD Trial with Dr. Charles Wykoff
Keyvan Koushan, MD, FRCSC
Member Podcasts
2017

Category: wet AMD

See more